Interstitial hyperthermia of the prostate in combination with brachytherapy

Kukielka, A.; Hetnał, Marcin; Brandys, Piotr; Walasek, Tomasz; Dąbrowski, Tomasz; Pluta, Elżbieta; Nahajowski, D.; Kudzia, R.

doi:10.1007/s00066-013-0321-6

Cited by 10 publications

(7 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Likewise, reports of complications associated with HDRBT þ IHT are scarce. The group of patients which we analysed in two earlier articles published in 2013 and 2014 [17,18] largely overlaps with the patient group analysed in this work, thus obviating any comparative effort.…”

Section: Evaluation Of Early Hdrbt 1 Iht Complicationsmentioning

confidence: 98%

“…So far, no randomised phase III studies of prostate cancer treated with hyperthermia have been conducted. Most of the available publications concerning phase I and II studies refer to deep hyperthermia [2,[11][12][13]15] and transrectal hyperthermia [16], with only a few studies on interstitial hyperthermia [17][18][19][20].…”

Section: Purposementioning

confidence: 99%

“…The procedure of HDRBT combined with IHT has been described elsewhere [17] and is briefly summarised here. The goal of IHT was to heat the prostate to 41-43 C for 60 min immediately before delivering each HDRBT fraction.…”

Section: Brachytherapy and Hyperthermia Proceduresmentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of tolerance and toxicity of high-dose-rate brachytherapy boost combined with interstitial hyperthermia for prostate cancer

Kukielka

Hetnał²,

Bereza

2016

International Journal of Hyperthermia

View full text Add to dashboard Cite

Purpose The aim of this retrospective study was to evaluate the tolerance and early as well as late toxicity of high dose rate brachytherapy (HDRBT) boost combined with interstitial hyperthermia (IHT) in patients treated for prostate cancer. Material and methods Between January 2011 and June 2013 76 patients diagnosed with prostate cancer received treatment consisting of external beam radiotherapy (EBRT), followed by a HDRBT boost combined with IHT. IHT was performed before each brachytherapy fraction. Results The median follow-up time was 26.3 months (range 7-43 months). Early genitourinary (GU) grade 1 and 2 toxicities were common, but only two patients (2.6%) experienced acute urinary retention requiring temporary catheterisation (grade 2 toxicity). No grade 3 or 4 genitourinary or gastrointestinal toxicities were observed. In the group analysed, 59 of 76 patients had follow-up times longer than 18 months. The incidence of grade 2 late toxicity in the group studied did not exceed 23.7%. There were no late grade 2 or higher complications from the gastrointestinal tract. Conclusions The tolerance of HDRBT boost combined with IHT is good. The profile and the percentage of early and late complications are acceptable.

show abstract

Section: Evaluation Of Early Hdrbt 1 Iht Complicationsmentioning

confidence: 98%

Section: Purposementioning

confidence: 99%

See 1 more Smart Citation

Evaluation of tolerance and toxicity of high-dose-rate brachytherapy boost combined with interstitial hyperthermia for prostate cancer

Kukielka

Hetnał²,

Bereza

2016

International Journal of Hyperthermia

View full text Add to dashboard Cite

show abstract

“…The recommended number of thermometry locations is given in Table 1, although a larger number of thermometry locations matching or exceeding number of independent applicators is preferred. A good example of a thermometry scheme is given by Kukielka et al [50].…”

Section: Catheter Implantationmentioning

confidence: 99%

Quality assurance guidelines for interstitial hyperthermia

Trefná

Schmidt

Rhoon

et al. 2019

International Journal of Hyperthermia

View full text Add to dashboard Cite

Quality assurance (QA) guidelines are essential to provide uniform execution of clinical hyperthermia treatments and trials. This document outlines the clinical and technical consequences of the specific properties of interstitial heat delivery and specifies recommendations for hyperthermia administration with interstitial techniques. Interstitial hyperthermia aims at tumor temperatures in the 40-44 C range as an adjunct to radiation or chemotherapy. The clinical part of this document imparts specific clinical experience of interstitial heat delivery to various tumor sites as well as recommended interstitial hyperthermia workflow and procedures. The second part describes technical requirements for quality assurance of current interstitial heating equipment including electromagnetic (radiative and capacitive) and ultrasound heating techniques. Detailed instructions are provided on characterization and documentation of the performance of interstitial hyperthermia applicators to achieve reproducible hyperthermia treatments of uniform high quality. Output power and consequent temperature rise are the key parameters for characterization of applicator performance in these QA guidelines. These characteristics determine the specific maximum tumor size and depth that can be heated adequately. The guidelines were developed by the ESHO Technical Committee with participation of senior STM members and members of the Atzelsberg Circle.

show abstract

“…The high prevalence of prostate cancer in the general population has led to exceptional changes in treatment during the past century, while the standard treatment for early prostate cancer is surgery or radiation therapy combined with hormone therapy. [ 1 2 ] In cases of recurrence of disease after failure of radiation therapy, optimal treatment remains unclear. [ 3 ] Several studies[ 3 4 ] have shown that hyperthermia combined with radiation appears as a promising therapy of locally advanced prostate cancer by enhancing the efficacy of treatment and survival rate of patients.…”

Section: Introductionmentioning

confidence: 99%